Quantcast

Latest Adalimumab Stories

2010-02-10 07:00:00

WALTHAM, Mass., Feb. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)--the leading therapy in the psoriasis drug market in 2008--will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States,...

2010-01-27 06:46:00

ABBOTT PARK, Ill., Jan. 27 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2009. Diluted earnings per share, excluding specified items, were $1.18, reflecting 11.3 percent growth, at the high end of Abbott's previous forecast. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.98, up 10.1 percent. Worldwide sales increased 10.6 percent to nearly $8.8 billion, including a...

2010-01-14 07:00:00

HORSHAM, Pa., Jan. 14 /PRNewswire/ -- Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA(TM) (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear today in The New England Journal of Medicine. The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week period. The first-of-its-kind head-to-head study comparing...

2010-01-04 07:00:00

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient...

2009-12-23 11:00:00

EXTON, Pa., Dec. 23 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the final wave of LaunchTrends®: Simponi and Cimzia report. The survey was completed by U.S. Rheumatologists (n=77) in late November 2009. BioTrends also conducted qualitative interviews with a subset (n=20) of the survey respondents to get an in-depth view of the sales and marketing messages being employed to differentiate the products. Over the course of the six month study...

2009-12-16 07:00:00

WALTHAM, Mass., Dec. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to responses from surveyed dermatologists, Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab (both interleukin inhibitors) will capture 22 percent of the biologics share in 2012 in the drug market for moderate to severe psoriasis. Among these two agents, Stelara will experience greater...

2009-12-09 07:06:00

WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease. Three times as many newly diagnosed second-line patients received a TNF-alpha inhibitor versus one year ago (15.2 percent versus 5.6...

2009-11-11 07:00:00

WALTHAM, Mass., Nov. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira....

2009-11-03 07:00:00

WALTHAM, Mass., Nov. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare...

2009-11-02 08:05:00

WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010. When asked why they would prescribe the drug, more than 60 percent of these rheumatologists cite the fact that, in clinical...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.